Fig. 2From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCProgression-free survival (PFS) (A) and overall survival (OS) (B) were significantly longer for patients treated with EGFR-TKI with bevacizumab (A+T) than EGFR-TKI monotherapy (T-single)Back to article page